We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Activation of Channel Proteins Slows Cancer Cell Growth and Impairs Metastatic Capability

By LabMedica International staff writers
Posted on 04 Jan 2017
A team of German researchers working with an aggressive breast cancer cell line showed that activation of TRPV1, a transient receptor potential channels protein, caused significant inhibition of cancer cell growth and induced apoptosis and necrosis.

Transient receptor potential (TRP) channels contribute to the regulation of intracellular calcium, which can promote cancer growth in cases of dysregulation of gene transcription and calcium-dependent pro-proliferative or anti-apoptotic mechanisms. More...
Several studies have begun to elucidate the roles of TRPV1, TRPV6, TRPM8, and TRPC1 in cancer progression; however, no study has examined the expression profiles of human TRP channels in breast cancer on a large scale.

In the current study, investigators at Ruhr-Universität Bochum (Germany) worked with the SUM149PT cell culture model system for aggressive triple-negative breast cancer. The investigators activated the cells' TRPV1 receptors by exposing the cell cultures for several hours or days to the compound capsaicin - an active ingredient of pungent substances such as chili peppers - or to helional - a chemical compound used as a perfume in soap and laundry detergent.

Results published in the December 13, 2016, issue of the journal Breast Cancer - Targets and Therapy revealed that activation of the TRPV1 receptor in the cell cultures by capsaicin or helional caused the cancer cells to divide more slowly and to die in increasingly larger numbers. The surviving cells showed decreased motility, which implied that their ability to form metastases was impaired.

"If we could switch on the TRPV1 receptor with specific drugs, this might constitute a new treatment approach for this type of cancer," said senior author Dr. Hanns Hat, professor of cell physiology at Ruhr-Universität Bochum. "An intake via food or inhalation is insufficient for this purpose."

Related Links:
Ruhr-Universität Bochum


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.